Centene CORP

Centene Corporation has announced a planned transition for its Chief Financial Officer role, with current CFO Drew Asher set to retire at the end of 2027 and Chris Neczypor named as his successor.

Centene Corporation announced its intention to redeem $500 million of its 4.25% Notes due December 15, 2027, with approximately $568.66 million remaining outstanding.

Centene Corporation announced the appointment of Theodore Pienkos as Corporate Controller and Chief Accounting Officer, while Kate Casso transitions to Senior Vice President, Finance Operations and Innovation.

Centene Corporation's senior management will reaffirm its 2026 full year GAAP and adjusted diluted EPS guidance during investor meetings this week.

Centene Corporation will present at the UBS 2025 Global Healthcare Conference, reaffirming its full year 2025 financial forecasts including a diluted loss per share not to exceed $(12.85) and adjusted diluted EPS of at least $2.00.

Centene Corporation reported a GAAP diluted loss per share of $(13.50) for the third quarter of 2025 due to a $6.7 billion goodwill impairment, while simultaneously raising its full-year adjusted diluted EPS forecast to at least $2.00.

Centene Corporation reported a significant net loss of $6.6 billion in Q3 2025, primarily due to a $6.7 billion goodwill impairment, despite an 18% increase in total revenues.

Centene Corporation reported a significant net loss in the second quarter of 2025, primarily driven by increased medical costs and a reduction in Marketplace risk adjustment revenue estimates, despite strong revenue growth.

Centene Corporation announces a strong first quarter in 2025, with significant revenue growth and improved earnings per share, driven by its Medicare and Commercial segments.

Centene Corporation's third-quarter results show revenue growth offset by increased medical costs and impacts from Medicaid redeterminations and Medicare Star ratings.

Centene Corporation's second quarter results show a 6% year-over-year revenue increase, driven by Marketplace growth, while navigating Medicaid redeterminations.

Centene Corporation's first quarter 2024 results show revenue growth and strategic adjustments amidst Medicaid redeterminations and divestitures.

Centene Corporation announces a 6% increase in total revenues to $163.1 billion and net earnings of $3.3 billion for the year ended December 31, 2024, while managing Medicaid redeterminations and preparing for Medicare Part D changes.

Centene Corporation's recent SEC filing details the characteristics of its common stock, including voting, liquidation, and dividend rights, as well as anti-takeover provisions and corporate governance structures.

Paul J Diaz, a Director of Centene Corp, received 2,771 shares of common stock on July 28, 2026.

Lauren M Tyler, a Director of Centene Corp, received 3,155 shares of common stock on July 17, 2026.

Centene Corp. director Lauren M. Tyler acquired 61 shares of common stock on June 30, 2026, through a transaction valued at $0.

Centene Corp. reports a director, Kenneth Tanji, acquired 581 shares of common stock on June 30, 2026.

Centene Corp. Director Theodore R. Samuels II reported the acquisition of 465 shares of common stock on June 30, 2026.

Centene Corp director Frederick H. Eppinger acquired 833 shares of common stock on June 30, 2026, increasing his direct beneficial ownership.

Centene Corporation faced significant disruption in 2025 with a GAAP diluted loss per share of $(13.53) and adjusted diluted EPS of $2.08, but anticipates over 40% growth in 2026, targeting adjusted diluted EPS exceeding $3.00.

Centene Corporation has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Centene reports strong 2024 financial results and outlines strategic priorities for 2025, focusing on Medicaid, Medicare, and the Health Insurance Marketplace.

James E. Murray has retired from Centene Corporation, effective March 29, 2024, consistent with his previously announced intention.

Centene Corporation has filed definitive additional proxy materials with the SEC.

Centene Corporation's 2024 proxy statement highlights the company's strategic advancements, financial performance, and commitment to sustainability and corporate governance.

Vanguard Capital Management has disclosed beneficial ownership of 35,946,964 shares, representing 7.3% of Centene Corp's common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership of Centene Corp common stock following an internal realignment.

AQR Capital Management, LLC and its parent company have reported a beneficial ownership of 6.47% in Centene Corp, totaling 31,798,738 shares.

FMR LLC and Abigail P. Johnson filed an amended Schedule 13G, reporting a 0.7% beneficial ownership in Centene Corp as of September 30, 2025.

Norges Bank, on behalf of the Government of Norway, has filed an amendment to disclose its beneficial ownership of 1.4% of Centene Corp's common stock.

Harris Associates L.P. and its general partner reported a beneficial ownership of 4.1% in Centene Corp's common stock as of June 30, 2025.